OSCA - Olaparib Standard of CAre Study

AstraZeneca2,123 enrolled

Overview

This study will be carried out as a retrospective, non-interventional observational review of medical records for patients in multiple countries with platinum-sensitive recurrent serous ovarian cancer. The objectives are to describe in a real-world population, treatment patterns, BRCA mutation testing and results, overall survival, health care utilization and also to estimate rates of selected treatment- and/or disease-related side effects

Study Type

OBSERVATIONAL

Enrollment

2,123

Conditions

Platinum-sensitive Recurrent Serous Ovarian Cancer

Interventions

Data CollectionOTHER

Colleciton of data from medical records only

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. First determined to have platinum-sensitive recurrent serous ovarian cancer between January 1, 2009, and December 31, 2013 (study entry period), as defined by no evidence of disease progression for at least 6 months after completion of a first-line platinum-based chemotherapy regimen; the first date of platinum-sensitive recurrence between January 1, 2009 and December 31, 2013 will define the study index date. 2. At least 18 years of age on the index date. 3. Fully documented medical history related to the patient's ovarian cancer treatment beginning with initial diagnosis of serous ovarian cancer. 4. Patients can be either alive or deceased at the time of medical record abstraction. Exclusion Criteria: 1\. Ever taken an investigational product as part of an interventional clinical trial for ovarian cancer.

Locations (199)

Outcomes

Primary Outcomes

Best response to therapy and date of response for each subsequent therapy line post-index

Response categories: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) Criteria on which physicians determined therapy response also will be captured (e.g., symptoms, radiological and/or other imaging findings, CA-125 levels, physical exam, or other criteria).

Time frame: Data will be collected retrospectively from medical records

Secondary Outcomes

Progression-free survival, by therapy line

Defined as time from initiation of the therapy line (including the required first-line platinum-based chemotherapy) until the earliest of progression, death, or end of follow-up (for censored observations) Criteria on which physicians determined progression also will be captured (e.g., symptoms, radiological and/or other imaging findings, CA-125 levels, physical exam, or other criteria)

Time frame: Data will be collected retrospectively from medical records

Overall survival, calculated from various time points

From first diagnosis of ovarian cancer until death or end of follow-up, whichever is earliest From initiation of the required first-line platinum-based chemotherapy regimen until death or end of follow-up, whichever is earliest From the index date (first determination of platinum-sensitive recurrence) until death or end of follow-up, whichever is earliest From initiation of each subsequent, post-index therapy line until death or end of follow-up, whichever is earliest

Time frame: Data will be collected retrospectively from medical records

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Research Site

Ballarat, Australia

Research Site

Birtinya, Australia

Research Site

Campbelltown, Australia

Research Site

East Melbourne, Australia

Research Site

Mandurah, Western Australia, Australia

Research Site

South Brisbane, Australia

Research Site

St Leonards, Australia

Research Site

Victoria, Australia

Research Site

Waratah, Australia

Research Site

Edegem, Belgium

...and 189 more locations